Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal. The US regulator has cleared ...
There was an error while loading. Please reload this page.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results